N²-[1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(1-methyl-1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine | 1220516-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: N²-[1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(1-methyl-1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
• 英文别名: N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(1-methyl-1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine；2-N-((1S)-1-(5-Fluoropyrimidin-2-yl)ethyl)-4-N-(1-methylimidazol-4-yl)-7H-pyrrolo(2,3-d)pyrimidine-2,4-diamine；2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(1-methylimidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
• CAS: 1220516-48-2
• 化学式: C₁₆H₁₆FN₉
• 分子量: 353.362
• InChiKey: QHXBWJSQXSYAGG-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,4-二氯-7H吡咯[2,3-D]嘧啶 在 水 、 四丁基硫酸氢铵 、 三乙胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙腈 、 正丁醇 为溶剂， 反应 5.5h， 生成 N²-[1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(1-methyl-1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
  参考文献：
  名称：

  Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors

  摘要：

  Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.

  DOI：

  10.1021/jm401546n

文献信息

• [EN] HETEROCYCLIC JAK KINASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE JAK
  申请人：ASTRAZENECA AB

  公开号：WO2010038060A1

  公开（公告）日：2010-04-08

  The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

  本发明涉及式（I）化合物及其盐、药物组合物、使用方法和制备方法。这些化合物可用于治疗骨髓增生性疾病和癌症。
• HETEROCYCLIC JAK KINASE INHIBITORS
  申请人：Chuaqui Claudio Edmundo

  公开号：US20110201628A1

  公开（公告）日：2011-08-18

  The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

  本发明涉及公式（I）的化合物及其盐，制药组合物，使用方法和制备方法。这些化合物提供了治疗骨髓增生性疾病和癌症的方法。